Skip to content

Study · Randomized controlled trial · 2017

2 results

The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.

Pokala N, Adams-Huet B, Li X, Harrison LB, Vanderheiden A, Lingvay I

Diabetes, obesity & metabolism12 Jun 2017Cited by 4 (Europe PMC)

PMID28608447 (opens in a new tab)DOI10.1111/dom.12939 (opens in a new tab)PepBankPUB-28608447
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients treated with high-dose insulin, treatment with liraglutide was the strongest predictor of HbA1c improvement, regardless of baseline characteristics.

    In plain wordsIn people on high-dose insulin, liraglutide treatment was the best predictor of lower HbA1c compared with placebo, whatever their starting characteristics.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c improvement
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Improvement in HbA1c was best predicted by treatment with liraglutide, followed by higher baseline HbA1c, BMI and age.
    2 context sentences
    Summary · context
    liraglutide significantly improved glycaemic control and led to weight loss regardless of patients' baseline characteristics
    Summary · context
    In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients treated with high-dose insulin, weight change was associated only with liraglutide treatment, independent of baseline characteristics; liraglutide led to weight loss.

    In plain wordsIn people on high-dose insulin, liraglutide treatment, not their starting characteristics, was linked to weight loss compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Changes in weight were only associated with liraglutide treatment, independent of all baseline characteristics.
    2 context sentences
    Summary · context
    liraglutide significantly improved glycaemic control and led to weight loss regardless of patients' baseline characteristics
    Summary · context
    In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.